ClinicalTrials.gov homepage. --- Either ISSN or Journal title must be supplied.. [http://www.clinicaltrials.gov]
Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials. 1998, 19: 178-187. 10.1016/S0197-2456(97)00118-9.
Article
CAS
PubMed
Google Scholar
Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.
Article
CAS
PubMed
Google Scholar
Haidich AB, Ioannidis JP: Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol. 2001, 154: 873-880. 10.1093/aje/154.9.873.
Article
CAS
PubMed
Google Scholar
Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006, 367: 1057-1065. 10.1016/S0140-6736(06)68350-5.
Article
CAS
PubMed
Google Scholar
Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000, 283: 1007-1015. 10.1001/jama.283.8.1007.
Article
CAS
PubMed
Google Scholar
Gómez-Isla T, Blesa R, Boada M, Clarimón J, Del Ser T, Domenech G, Ferro JM, Gómez-Ansón B, Manubens JM, Martínez-Lage JM, Muñoz D, Peña-Casanova J, Torres F, TRIMCI Study Group: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008, 22: 21-29.
Article
PubMed
Google Scholar
Vozdolska R, Sano M, Aisen P, Edland SD: The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009, 6: 126-132. 10.1177/1740774509103485.
Article
PubMed Central
PubMed
Google Scholar
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH: Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease: A Randomized Controlled Trial. JAMA. 2009, 302: 2557-2564. 10.1001/jama.2009.1866.
Article
PubMed Central
CAS
PubMed
Google Scholar
Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009, 73: 2061-2070. 10.1212/WNL.0b013e3181c67808.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9: 363-372. 10.1016/S1474-4422(10)70043-0.
Article
CAS
PubMed
Google Scholar
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348: 1333-1341. 10.1056/NEJMoa013128.
Article
CAS
PubMed
Google Scholar
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004, 291: 317-324. 10.1001/jama.291.3.317.
Article
CAS
PubMed
Google Scholar
Albert SM, Sano M, Marder K, Jacobs DM, Brandt J, Albert M, Stern Y: Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997, 49: 38-43.
Article
CAS
PubMed
Google Scholar
Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB: Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002, 59: 1737-1746. 10.1001/archneur.59.11.1737.
Article
PubMed
Google Scholar
Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R: Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994, 271: 1004-1010. 10.1001/jama.271.13.1004.
Article
CAS
PubMed
Google Scholar
Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy GM, Olin JT, Regier D, Sano M, Mintzer JE: Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr. 2007, 19: 539-558. 10.1017/S104161020700511X.
Article
PubMed
Google Scholar
Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, Hebert LE, Aggarwal N, Beckett LA, Joglekar R, Berry-Kravis E, Schneider J: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003, 60: 185-189. 10.1001/archneur.60.2.185.
Article
PubMed
Google Scholar
Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001, 56: 49-56.
Article
CAS
PubMed
Google Scholar
Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010, 6: 158-194. 10.1016/j.jalz.2010.01.009.
Article
Google Scholar
Karlawish JH, Casarett D, Klocinski J, Sankar P: How do AD patients and their caregivers decide whether to enroll in a clinical trial?. Neurology. 2001, 56: 789-792.
Article
CAS
PubMed
Google Scholar
Carr SA, Davis R, Spencer D, Smart M, Hudson J, Freeman S, Cooper GE, Schmitt FA, Markesbery WR, Danner D, Jicha GA: Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord. 2010, 24: 165-170. 10.1097/WAD.0b013e3181aba927.
Article
PubMed Central
PubMed
Google Scholar
Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007, 69: 2197-2204. 10.1212/01.wnl.0000271090.28148.24.
Article
PubMed
Google Scholar
Lai JM, Hawkins KA, Gross CP, Karlawish JH: Self-reported distress after cognitive testing in patients with Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2008, 63: 855-859.
Article
PubMed Central
PubMed
Google Scholar
Hirschman KB, Joyce CM, James BD, Xie SX, Karlawish JH: Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?. Gerontologist. 2005, 45: 381-388.
Article
PubMed
Google Scholar
Sugarman J, Cain C, Wallace R, Welsh-Bohmer KA: How proxies make decisions about research for patients with Alzheimer's disease. J Am Geriatr Soc. 2001, 49: 1110-1119. 10.1046/j.1532-5415.2001.49218.x.
Article
CAS
PubMed
Google Scholar
Connell CM, Shaw BA, Holmes SB, Foster NL: Caregivers' attitudes toward their family members' participation in Alzheimer disease research: implications for recruitment and retention. Alzheimer Dis Assoc Disord. 2001, 15: 137-145. 10.1097/00002093-200107000-00005.
Article
CAS
PubMed
Google Scholar
Elad P, Treves TA, Drory M, Verchovsky R, Klimovitsky S, Ben-Laish S, Yaron S, Ginzburg K, Korczyn AD: Demented patients' participation in a clinical trial: factors affecting the caregivers' decision. Int J Geriatr Psychiatry. 2000, 15: 325-330. 10.1002/(SICI)1099-1166(200004)15:4<325::AID-GPS117>3.0.CO;2-9.
Article
CAS
PubMed
Google Scholar
Mastwyk M, Macfarlane S, LoGiudice D, Sullivan KA: Why participate in an Alzheimer's disease clinical trial? Is it of benefit to carers and patients?. Int Psychogeriatr. 2003, 15: 149-156. 10.1017/S1041610203008834.
Article
PubMed
Google Scholar
Mastwyk M, Ritchie CW, LoGiudice D, Sullivan KA, Macfarlane S: Carer impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it?. Int Psychogeriatr. 2002, 14: 39-45. 10.1017/S1041610202008268.
Article
PubMed
Google Scholar
Karlawish J, Cary MS, Rubright J, Tenhave T: How redesigning AD clinical trials might increase study partners' willingness to participate. Neurology. 2008, 71: 1883-1888. 10.1212/01.wnl.0000336652.05779.ea.
Article
PubMed Central
PubMed
Google Scholar
Brodaty H, Green A: Defining the role of the caregiver in Alzheimer's disease treatment. Drugs Aging. 2002, 19: 891-898. 10.2165/00002512-200219120-00001.
Article
PubMed
Google Scholar
Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC: The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999, 14: 701-710. 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#.
Article
CAS
PubMed
Google Scholar
Grafstrom M, Winblad B: Family burden in the care of the demented and nondemented elderly--a longitudinal study. Alzheimer Dis Assoc Disord. 1995, 9: 78-86. 10.1097/00002093-199509020-00004.
Article
CAS
PubMed
Google Scholar
Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005, 62: 753-757. 10.1001/archneur.62.5.753.
Article
PubMed
Google Scholar
Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, Raskind M, Peskind E, Newhouse P, Sack D, De Souza E, Sadowsky C, Roberts E, DHEA-Alzheimer's Disease Collaborative Research: DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology. 2003, 60: 1071-1076.
Article
CAS
PubMed
Google Scholar
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003, 289: 2819-2826. 10.1001/jama.289.21.2819.
Article
CAS
PubMed
Google Scholar
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005, 352: 2379-2388. 10.1056/NEJMoa050151.
Article
CAS
PubMed
Google Scholar
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010, 74: 956-964. 10.1212/WNL.0b013e3181d6476a.
Article
CAS
PubMed
Google Scholar
Edland SD, Emond JA, Aisen PS, Petersen RC: NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010, 24: 159-164. 10.1097/WAD.0b013e3181c9983f.
Article
PubMed Central
PubMed
Google Scholar
Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001, 15: 169-173. 10.1097/00002093-200110000-00002.
Article
CAS
PubMed
Google Scholar
Helmer C, Peres K, Letenneur L, Guttierez-Robledo LM, Ramaroson H, Barberger-Gateau P, Fabrigoule C, Orgogozo JM, Dartigues JF: Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord. 2006, 22: 87-94. 10.1159/000093459.
Article
PubMed
Google Scholar
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003, 60: 1119-1122. 10.1001/archneur.60.8.1119.
Article
PubMed
Google Scholar
Schneider LS, Olin JT, Lyness SA, Chui HC: Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997, 45: 923-928.
Article
CAS
PubMed
Google Scholar
Treves TA, Verchovsky R, Klimovitsky S, Korczyn AD: Recruitment rate to drug trials for dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2000, 14: 209-211. 10.1097/00002093-200010000-00004.
Article
CAS
PubMed
Google Scholar
Schindler RJ: Study design considerations: conducting global clinical trials in early Alzheimer's disease. J Nutr Health Aging. 2010, 14: 312-314. 10.1007/s12603-010-0071-4.
Article
CAS
PubMed
Google Scholar
Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA: Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009, 360: 816-823. 10.1056/NEJMsb0803929.
Article
CAS
PubMed
Google Scholar
Homma A: Current status of clinical trials for Alzheimer-type dementia in Japan: strategies to facilitate the development of antidementia drugs. Alzheimer Dis Assoc Disord. 2000, 14 (Suppl 1): S123-126.
Article
PubMed
Google Scholar
Gold M: Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007, 68: 430-438. 10.4088/JCP.v68n0313.
Article
CAS
PubMed
Google Scholar
Wisconsin Registry for Alzheimer's Prevention (WRAP). --- Either ISSN or Journal title must be supplied.. [http://www.wai.wisc.edu/research/wrap.html]
PatientsLikeMe homepage. --- Either ISSN or Journal title must be supplied.. [http://www.patientslikeme.com]
Fox S: Older Americans and the internet. 2004 Project Report. 2004, Washington, DC: The Pew Internet & American Life Project
Google Scholar
Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ: Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010, 6: 89-97. 10.1016/j.jalz.2010.01.008.
Article
PubMed Central
PubMed
Google Scholar
Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005, 30: 1204-1215. 10.1038/sj.npp.1300690.
Article
CAS
PubMed
Google Scholar
Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R: Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007, 6: 501-512. 10.1016/S1474-4422(07)70109-6.
Article
CAS
PubMed
Google Scholar
Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS: Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008, 70: 2024-2035. 10.1212/01.wnl.0000303815.69777.26.
Article
CAS
PubMed
Google Scholar
Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S: Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004, 63: 651-657.
Article
CAS
PubMed
Google Scholar
Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK: Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009, 72: 1555-1561. 10.1212/01.wnl.0000344650.95823.03.
Article
CAS
PubMed
Google Scholar
Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-215. 10.1016/S0140-6736(08)61074-0.
Article
CAS
PubMed
Google Scholar
Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG: Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology. 2003, 61: 1498-1502.
Article
CAS
PubMed
Google Scholar
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212/01.WNL.0000159740.16984.3C.
Article
CAS
PubMed
Google Scholar
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001/archneur.65.8.1031.
Article
PubMed Central
PubMed
Google Scholar
Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R: IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007, 69: S14-22. 10.1212/01.wnl.0000281847.17519.e0.
Article
CAS
PubMed
Google Scholar
Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007, 22: 456-467. 10.1002/gps.1788.
Article
PubMed
Google Scholar
Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6: 246-254.
CAS
PubMed
Google Scholar
Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ: High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008, 300: 1774-1783. 10.1001/jama.300.15.1774.
Article
PubMed Central
CAS
PubMed
Google Scholar
van Dyck CH, Tariot PN, Meyers B, Malca Resnick E: A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007, 21: 136-143. 10.1097/WAD.0b013e318065c495.
Article
CAS
PubMed
Google Scholar
Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007, 69: 459-469. 10.1212/01.wnl.0000266627.96040.5a.
Article
CAS
PubMed
Google Scholar
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000, 54: 2269-2276.
Article
CAS
PubMed
Google Scholar
Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000, 54: 2261-2268.
Article
CAS
PubMed
Google Scholar
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997, 336: 1216-1222. 10.1056/NEJM199704243361704.
Article
CAS
PubMed
Google Scholar
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001, 57: 613-620.
Article
CAS
PubMed
Google Scholar